North America Biosimulation Market Report and Forecast 2024-2032

North America Biosimulation Market Outlook

The global biosimulation market size was valued at USD 3.5 billion in 2023, with North America holding a substantial market share. The market is driven by technological advancements in the biosimulation software. It is expected to grow at a CAGR of 16.90% during the forecast period of 2024-2032, with the values likely to attain USD 14.1 billion by 2032.

Key Takeaways

• With over 2 million new cases of cancer projected to occur in the United States in 2024, biosimulation stands as a promising approach to accelerate oncology drug development and tackle the rising burden of the disease.

• In December 2024, Certara, Inc. acquired Applied BioMath to industrialize quantitative systems pharmacology (QSP) biosimulation methods. Increased merger and acquisition initiatives among the key market players are expected to make biosimulation software more accessible and augment the North America biosimulation market share in the forecast period.

• The market is witnessing increased biosimulation applications in the drug development process. In January 2023, Cellworks announced the launch of two business units that will employ its in-house biosimulation and computational biosimulation model (CBM) to streamline clinical trials and save time and money in drug development processes.

North America Biosimulation Market Analysis

Biosimulation is a robust tool that can simulate complex biological systems, allowing researchers to predict drug behavior, reduce time and costs associated with drug development, and optimize treatment strategies. In North America, biosimulation services and software are increasingly employed for disease modeling, risk assessment of pharmaceutical products, and toxicology, among others. The expansion of biosimulation applications in various domains is likely to boost the North America biosimulation market growth in the coming years.

According to the American Cancer Society, over 2 million new cases of cancer are projected to occur in the United States in 2024. Moreover, cancer would be responsible for more than 611,000 deaths in the region in 2024. Biosimulation can predict long-term outcomes of therapies for chronic diseases including cancer, thus, it stands as a promising approach to accelerate oncology drug development and tackle the rising burden of the disease. Consequently, the market share for biosimulation systems is expected to rise in the forecast period.

One of the major North America biosimulation market trends is the increased merger and acquisition initiatives among the key market players. In December 2024, Certara, Inc. (a United States-based biotechnology company specializing in biosimulation software and technology) acquired Applied BioMath (a leading developer of mathematical modeling and biosimulation platforms in the United States) to industrialize quantitative systems pharmacology (QSP) biosimulation methods by sharing scientific and computational expertise from the companies’ existing biosimulation and artificial intelligence portfolios. This acquisition will allow the combined teams to make QSP biosimulation approach, which can predict biomarkers, endpoints, and optimal dosing regimens, more accessible and available across the industry. The rising access to such biosimulation platforms that can lead to safer drug development is expected to elevate the market value in the forecast period.

North America biosimulation market demand is driven by advancements in computational power and software capabilities that are resulting in accurate biosimulation and accelerated drug development timelines. Such advancements are encouraging leading biosimulation companies to expand their business domains and customer base. In January 2023, Cellworks, a life sciences technology company in the United States, announced the launch of two business units that will employ its in-house biosimulation and computational biosimulation model (CBM) to streamline clinical trials and save time along with money in the drug development processes. Thus, the new business will be focusing on silico approaches to test potential precision oncology drugs and deliver the new therapies to patients faster. This also indicates a rising utilization of biosimulation methods in the drug development process, which is likely to fuel market growth in North America.

North America Biosimulation Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

North America Biosimulation Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Dassault Systems

• VeriSIM Life

• Certara Inc

• Genedata AG

• SimBioSys

• Physiomics PlC

• INOSIM Software Gmbh

• Schrodinger Inc.

• Simulation Plus Inc.

• Cadence Design Systems, Inc (OpenEye Scientific)

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

North America Biosimulation Market Report Snapshots

North America Biosimulation Market Size

North America Biosimulation Market Analysis

North America Biosimulation Companies